CoChat

A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis

Open access
Thomas, Sarah, Thomas, Peter W, Kersten, Paula, Jones, Rosemary, Green, Colin, Nock, Alison, Slingsby, Vicky, Smith, Angela Davies, Baker, Roger, Galvin, Kathleen T, Hillier, Charles · 2013 · Journal of Neurology, Neurosurgery & Psychiatry
Cited by 146

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Fatigue is a common and troubling symptom for people with multiple sclerosis (MS). AIM: To evaluate the effectiveness and cost-effectiveness of a six-session group-based programme for managing MS-fatigue (Fatigue: Applying Cognitive behavioural and Energy effectiveness Techniques to lifeStyle (FACETS)). METHODS: Three-centre parallel arm randomised controlled trial with economic evaluation. Patients with MS and significant fatigue were randomised to FACETS plus current local practice (FACETS) or current local practice alone (CLP), using concealed computer-generated randomisation. Participant blinding was not possible. Primary outcomes were fatigue severity (Fatigue Assessment Instrument), self-efficacy (Multiple Sclerosis-Fatigue Self-Efficacy) and disease-specific quality of life (Multiple Sclerosis Impact Scale (MSIS-29)) at 1 and 4 months postintervention (follow-up 1 and 2). Quality adjusted life years (QALYs) were calculated (EuroQoL 5-Dimensions questionnaire and the Short-form 6-Dimensions questionnaire). RESULTS: Between May 2008 and November 2009, 164 patients were randomised; primary outcome data were available for 146 (89%). Statistically significant differences favour the intervention group on fatigue self-efficacy at follow-up 1 (mean difference (MD) 9, 95% CI (4 to 14), standardised effect size (SES) 0.54, p=0.001) and follow-up 2 (MD 6, 95% CI (0 to 12), SES 0.36, p=0.05) and fatigue severity at follow-up 2 (MD -0.36, 95% CI (-0.63 to -0.08), SES -0.35, p=0.01) but no differences for MSIS-29 or QALYs. No adverse events reported. Estimated cost per person for FACETS is £453; findings suggest an incremental cost-effectiveness ratio of £2157 per additional person with a clinically significant improvement in fatigue. CONCLUSIONS: FACETS is effective in reducing fatigue severity and increasing fatigue self-efficacy. However, it is difficult to assess the additional cost in terms of cost-effectiveness (ie, cost per QALY) as improvements in fatigue are not reflected in the QALY outcomes, with no significant differences between FACETS and CLP. The strengths of this trial are its pragmatic nature and high external validity. TRIAL REGISTRATION: Current Controlled Trials ISRCTN76517470.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jnnp-2012-303816

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 30

  1. Krupp, 2010, Multiple sclerosis-associated fatigue, Expert Rev Neurother, 10, 1437, 10.1586/ern.10.99 · DOI · Paper page
  2. Branas, 2000, Treatments for fatigue in multiple sclerosis: a rapid and systematic review, Health Technol Ass, 4, 1
  3. Costello, 2003, Differential diagnosis and management of fatigue in multiple sclerosis: considerations for the nurse, J Neurosci Nurs, 35, 139, 10.1097/01376517-200306000-00003 · DOI
  4. Grima, 2000, Cost and health related quality of life consequences of multiple sclerosis, Mult Scler, 6, 91, 10.1177/135245850000600207 · DOI · Paper page
  5. White, 2008, Invisible and visible symptoms of multiple sclerosis: which are more predictive of health distress?, J Neurosci Nurs, 40, 85, 10.1097/01376517-200804000-00007 · DOI · Paper page
  6. Bakshi, 2003, Fatigue associated with multiple sclerosis: diagnosis, impact and management, Mult Scler, 9, 219, 10.1191/1352458503ms904oa · DOI · Paper page
  7. Mathiowetz, 2007, One-year follow-up to a randomized controlled trial of an energy conservation course for persons with multiple sclerosis, Int J Rehabil Res, 30, 305, 10.1097/MRR.0b013e3282f14434 · DOI
  8. Lee, 2008, Treatment of fatigue in multiple sclerosis: a systematic review of the literature, Int J Nurs Pract, 14, 81, 10.1111/j.1440-172X.2008.00670.x · DOI
  9. van Kessel, 2006, Understanding multiple sclerosis fatigue: a synthesis of biological and psychological factors, J Psychosom Res, 61, 583, 10.1016/j.jpsychores.2006.03.006 · DOI
  10. Thomas, 2010, Development and preliminary evaluation of a cognitive behavioural approach to fatigue management in people with multiple sclerosis, Patient Educ Couns, 78, 204, 10.1016/j.pec.2009.07.001 · DOI
  11. Thomas, 2010, Multi-centre parallel arm randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based cognitive behavioural approach to managing fatigue in people with multiple sclerosis, BMC Neurol, 10, 43, 10.1186/1471-2377-10-43 · DOI
  12. Krupp, 1989, The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus, Arch Neurol, 10, 1121, 10.1001/archneur.1989.00520460115022 · DOI · Paper page
  13. Hobart, 2004, Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome, Health Technol Assess, 8, 1, 10.3310/hta8090 · DOI · Paper page
  14. Schwartz, 1996, Measuring self-efficacy in people with multiple sclerosis: a validation study, Arch Phys Med Rehabil, 77, 394, 10.1016/S0003-9993(96)90091-X · DOI
  15. Ware, 1992, The MOS 36-item Short-Form health survey (SF-36):I. Conceptual framework and item selection, Med Care, 30, 473, 10.1097/00005650-199206000-00002 · DOI · Paper page
  16. Dolan, 1997, Modeling Valuations for EuroQol Health States, Med Care, 35, 1095, 10.1097/00005650-199711000-00002 · DOI
  17. Brazier, 2002, The estimation of a preference-based measure of health from the SF-36, J Health Econ, 21, 271, 10.1016/S0167-6296(01)00130-8 · DOI · Paper page
  18. Ryan, 2006, The validity and reliability of a novel activity monitor as a measure of walking, Br J Sports Med, 40, 779, 10.1136/bjsm.2006.027276 · DOI · Paper page
  19. Cohen, 1988, Statistical power analysis for the behavioral sciences
  20. Goligher, 2008, Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus, J Rheumatol, 35, 635
  21. Bauer, 2008, Evaluating group based interventions when control participants are ungrouped, 210
  22. Brazier, 2007, Measuring and valuing health for economic evaluation
  23. Altman, 1990, Randomisation and baseline comparisons in clinical trials, Lancet, 335, 149, 10.1016/0140-6736(90)90014-V · DOI · Paper page
  24. National Institute for Health and Clinical Excellence (NICE), June 2008, Guide to the methods of technology appraisal
  25. Ageing. Pharmaceutical Benefits Advisory Committee, December 2008, Australian Government Department of Health and
  26. Hemmett, 2004, What drives quality of life in multiple sclerosis?, Q J Med, 97, 671, 10.1093/qjmed/hch105 · DOI · Paper page
  27. Hobart, 2001, The SF-36 in multiple sclerosis: why assumptions must be tested, J Neurol Neurosurg Psychiatry, 71, 363, 10.1136/jnnp.71.3.363 · DOI · Paper page
  28. Opara, 2010, Quality of life in multiple sclerosis, J Med Life, 3, 352
  29. Fisk, 2005, A comparison of health utility measures for the evaluation of multiple sclerosis treatments, J Neurol Neurosurg Psychiatry, 76, 58, 10.1136/jnnp.2003.017897 · DOI · Paper page
  30. Hawton, 2012, Using the Multiple Sclerosis Impact Scale in treatment decision-making: Mapping from the MSIS-29 version 2 to the EQ-5D and the SF-6D, Value Health, 15, 1084, 10.1016/j.jval.2012.07.007 · DOI

Cited by

See all 146

Metadata

Authors
Thomas, S., Thomas, P. W., Kersten, P., Jones, R., Green, C., Nock, A., Slingsby, V., Smith, A. D., Baker, R., Galvin, K. T., & Hillier, C.
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
2013-05-21
Volume
84
Issue
10
Pages
1092-1099
ISSN
  • 0022-3050 (ISSN-L)
  • 1468-330X
OpenAlex
W2140012944
Cited by
146
References
9
FWCI
7.34
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. https://app.cochat.ai/papers/10.1136/jnnp-2012-303816
The paper
Thomas, S., Thomas, P. W., Kersten, P., Jones, R., Green, C., Nock, A., Slingsby, V., Smith, A. D., Baker, R., Galvin, K. T., & Hillier, C. (2013). A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2012-303816

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.